SCHEMBL6775183

SCHEMBL6775183

Cc1cccc(CCC(=O)OC(C)(C)C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
P2RX7 Q99572 1/20 0.37
ALDH1A1 P00352 3/20 0.36
HSD17B3 P37058 1/20 0.36
GRM5 P41594 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
RAB9A P51151 1/20 0.36
GLA P06280 1/20 0.36
ADORA2A P29274 2/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374158 0.88 KMT2A (0.46) KMT2AMEN1OPRM1OPRD1NPSR1
SCHEMBL946003 0.85 NPSR1 (0.42) KMT2ANPSR1ALDH1A1ADORA2AKCNH2
SCHEMBL24621514 0.84 NPSR1 (0.41) KMT2ANPSR1ALDH1A1KCNH2KDM4E
SCHEMBL946119 0.84 NPSR1 (0.41) KMT2AMEN1NPSR1ALDH1A1RAB9A
SCHEMBL10966118 0.83 KMT2A (0.50) KMT2AMEN1OPRM1OPRD1NPSR1
SCHEMBL3886140 0.81 CYP4F2 (0.50) KMT2AMEN1OPRM1OPRD1SMN1; SMN2
SCHEMBL13199720 0.80 NPSR1 (0.36) KMT2AMEN1NPSR1ALDH1A1RAB9A
SCHEMBL2962806 0.80 ALDH1A1 (0.38) KMT2ANPSR1ALDH1A1GLA
SCHEMBL19837458 0.79 ALDH1A1 (0.47) KMT2AMEN1OPRM1OPRD1NPSR1
SCHEMBL27965286 0.79 P2RX7 (0.44) KMT2AMEN1OPRM1OPRD1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed